Economic value of influenza vaccination
Economic value of influenza vaccination
复制标题
DOI：
10.4161/hv.8.1.18420
复制
发表时间：
2012-01-01
影响因子：
4.8
通讯作者：
Ricciardi, Walter
中科院分区：
文献类型：
--
作者：
de Waure, Chiara;Veneziano, Maria Assunta;Ricciardi, Walter
流感流行造成高死亡率和发病率，特别是在老年人和高风险群体中。本综述旨在评估这些群体接种疫苗的经济价值。在PubMed上检索了1990年1月至2011年5月期间流感疫苗接种与无干预相比的全面经济评价。只考虑了涉及老年人和高风险群体的经济评价。通过Drummond的检查表评估所选文章的质量。纳入了16项成本效益分析和4项成本效益分析：总体而言，研究质量相当好。几乎所有研究都证明疫苗接种具有成本效益或节省成本，独立于分析的角度和类型。从药物经济学的角度来看，流感疫苗接种是一种值得的干预措施，无论如何，为了保证结果的可比性和可转移性，应该对方法进行标准化。
Influenza epidemics are responsible for high mortality and morbidity rates in particular among elderly and high risk groups. This review is aimed at assessing the economic value of vaccination in these groups. A search of full economic evaluations of influenza vaccination in comparison with no interventions was performed on PubMed from January 1990 to May 2011. Only economic evaluations dealing with elderly and high risk groups were considered. The quality of selected articles was assessed through Drummond's checklist. Sixteen cost-effectiveness analyses and four cost-benefit analyses were included: overall, the quality of studies was fairly good. The vaccination was demonstrated to be cost-effective or cost-saving in almost all studies, independently by the perspective and the type of analysis. Influenza vaccination is a worthwhile intervention from the pharmacoeconomic view-point, anyway a standardization of methods should be desirable in order to guarantee the comparability and transferability of results.